BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28277880)

  • 1. Genomic tests to guide prostate cancer management following diagnosis.
    Colicchia M; Morlacco A; Cheville JC; Karnes RJ
    Expert Rev Mol Diagn; 2017 Apr; 17(4):367-377. PubMed ID: 28277880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Markers in Prostate Cancer Decision Making.
    Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
    Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of biomarkers in the diagnosis and management of prostate cancer.
    Uhr A; Glick L; Gomella LG
    Can J Urol; 2020 Aug; 27(S3):24-27. PubMed ID: 32875999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.
    Nguyen JK; Magi-Galluzzi C
    Adv Anat Pathol; 2018 Sep; 25(5):293-303. PubMed ID: 29727322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.
    Ross AE; D'Amico AV; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):1-6. PubMed ID: 26123120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
    Eggener SE; Rumble RB; Armstrong AJ; Morgan TM; Crispino T; Cornford P; van der Kwast T; Grignon DJ; Rai AJ; Agarwal N; Klein EA; Den RB; Beltran H
    J Clin Oncol; 2020 May; 38(13):1474-1494. PubMed ID: 31829902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Predictors of Outcome in Prostate Cancer.
    Boström PJ; Bjartell AS; Catto JW; Eggener SE; Lilja H; Loeb S; Schalken J; Schlomm T; Cooperberg MR
    Eur Urol; 2015 Dec; 68(6):1033-44. PubMed ID: 25913390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel biomarkers and genomic tests in prostate cancer: a critical analysis.
    Falzarano SM; Ferro M; Bollito E; Klein EA; Carrieri G; Magi-Galluzzi C
    Minerva Urol Nefrol; 2015 Sep; 67(3):211-31. PubMed ID: 26054411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in prostate cancer - Current clinical utility and future perspectives.
    Kretschmer A; Tilki D
    Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular biomarkers and prognostic factors for prostate cancer].
    Kretschmer A; Tolkach Y; Ellinger J; Kristiansen G
    Urologe A; 2017 Jul; 56(7):933-944. PubMed ID: 28573413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy.
    Glicksman RM; Berlin A
    Cancer J; 2020; 26(1):13-20. PubMed ID: 31977380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic associations of gene expression signatures in prostate cancer tissue.
    Nguyen HG; Welty CJ; Cooperberg MR
    Curr Opin Urol; 2015 Jan; 25(1):65-70. PubMed ID: 25405934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic testing for localized prostate cancer: where do we go from here?
    Loeb S; Ross AE
    Curr Opin Urol; 2017 Sep; 27(5):495-499. PubMed ID: 28661898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.
    Moschini M; Spahn M; Mattei A; Cheville J; Karnes RJ
    BMC Med; 2016 Apr; 14():67. PubMed ID: 27044421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer genomics: comparing results from three molecular assays.
    Alam S; Tortora J; Staff I; McLaughlin T; Wagner J
    Can J Urol; 2019 Jun; 26(3):9758-9762. PubMed ID: 31180305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commercialized biomarkers: new horizons in prostate cancer diagnostics.
    Murphy L; Prencipe M; Gallagher WM; Watson RW
    Expert Rev Mol Diagn; 2015 Apr; 15(4):491-503. PubMed ID: 25711191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
    Palapattu GS
    J Urol; 2017 Aug; 198(2):265-266. PubMed ID: 28629664
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic testing for the clinician in prostate cancer.
    López-Campos F; Linares-Espinós E; Maldonado Pijoan X; Sancho Pardo G; Morgan TM; Martínez-Ballesteros C; Martínez-Salamanca J; Couñago F
    Expert Rev Mol Diagn; 2020 Sep; 20(9):933-946. PubMed ID: 32885704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.